A proportion of patients with JAK2 mutations develop myeloproliferative neoplasms (MPN), characterized by the proliferation of stem cells such as mature granulocytes (primary myelofibrosis), red blood cells (polycythemia vera), and/or platelets (essential thrombocythemia).15 Here, JAK2 is linked to myeloproliferative disorder.